d[Leu4,Lys8]-VP

Discontinued Product

3127 has been discontinued.

View all Vasopressin Receptors products.
说明: Selective V1B agonist
说明书
引用文献 (1)
评论
文献 (1)

生物活性 for d[Leu4,Lys8]-VP

d[Leu4,Lys8]-VP is a selective vasopressin V1B receptor agonist (Ki values are 0.16, 64, 100 and 3800 nM for V1B, oxytocin, V2 and V1A receptors respectively). Displays weak antidiuretic, vasopressor and in vitro oxytocic activities.

技术数据 for d[Leu4,Lys8]-VP

分子量 1026.2
公式 C47H67N11O11S2
序列 XYFLNCPKG

(Modifications: X = Mpr, Gly-9 = C-terminal amide, Disulfide bridge between X-1 - Cys-6)

储存 Store at -20°C
CAS Number 42061-33-6
PubChem ID 44419030
InChI Key QGZMLGLFLYCDQT-PEAOEFARSA-N
Smiles CC(C)C[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for d[Leu4,Lys8]-VP

分析证书/产品说明书
选择另一批次:

按产品操作查看相关产品

查看全部 Vasopressin Receptor Agonists

关键词: d[leu4,Lys8]-VP, d[leu4,Lys8]-VP supplier, Selective, V1b, agonists, V2, Receptors, Vasopressin, 3127, Tocris Bioscience

1 篇 d[Leu4,Lys8]-VP 的引用文献

引用文献是使用了 Tocris 产品的出版物。 d[Leu4,Lys8]-VP 的部分引用包括:

Leroy et al (2018) A circuit from hippocampal CA2 to lateral septum disinhibits social aggression. Nature 564 213 PMID: 30518859


d[Leu4,Lys8]-VP 的评论

目前没有该产品的评论。 Be the first to review d[Leu4,Lys8]-VP and earn rewards!

Have you used d[Leu4,Lys8]-VP?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.